369 SOUTH SAN ANTONIO RD., LOS ALTOS, CA
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
Reports Full Year 2025 Financial Results and Recent Business Highlights
Announces $120 Million Private Placement Financing
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Changes in Board, Management or Compensation
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement